Trials / Not Yet Recruiting
Not Yet RecruitingNCT06885671
Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy
Phase II Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy: SHIFT-PB
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- British Columbia Cancer Agency · Academic / Other
- Sex
- Female
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Partial Breast Irradiation (PBI) is a targeted radiation approach commonly administered post-lumpectomy, specifically targeting the tumour bed. This targeted therapy reduces the exposure to other nearby tissues such as lungs, heart, and chest wall. However, traditional PBI treatment involves lengthy multiple fraction courses which presents a burden to patients from rural and remote communities, who must travel long distances to receive high quality cancer care. The purpose of this study is to compare single fraction (SF) PBI vs. multiple fraction (MF) PBI.
Detailed description
Radiation can be delivered in multiple fractions, or doses, and can take up to several weeks or months of treatment depending on the type of cancer. Radiation can also be offered in a single fraction. Both techniques have evidence for use in clinical care. Multiple fraction is offered to reduce the amount of radiation given at a single time that could reduce late toxicities. However, single fraction radiotherapy is more cost-effective and saves patient time. With this trial, we will compare single fraction vs. multiple fraction PBI in regards to their impact on quality of life, rates of provider and participant reported toxicities, and local control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Multiple Fraction PBI | Participants randomized to Arm 1 will receive PBI with a dose of 26 Gy in 5 daily fractions. |
| RADIATION | Single Fraction PBI | Participants randomized to Arm 2 will receive PBI in a single fraction with a dose of 13 Gy. |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
- First posted
- 2025-03-20
- Last updated
- 2025-11-17
Source: ClinicalTrials.gov record NCT06885671. Inclusion in this directory is not an endorsement.